Low-sodium oxybate reduces excessive daytime sleepiness and improves nighttime sleep quality in participants with narcolepsy
In a phase 4 open-label study of 34 participants with narcolepsy (NT1 or NT2), low-sodium oxybate (LXB) significantly reduced daytime sleepiness, with a least-squares mean change in Epworth Sleepiness Scale score of -7.7 (SE 0.9, P<0.0001). LXB also decreased transitions to lighter sleep stages by 13.1 (SE 2.9, P<0.0001), increased N3 (deep sleep) duration by 45.0 minutes (SE 8.8, P<0.0001), and reduced nocturnal awakenings by 3.2 (SE 0.9, P=0.0013). Most participants reported improved sleep quality and overall disease severity.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Low-sodium oxybate reduces excessive daytime sleepiness and improves nighttime sleep quality in participants with narcolepsy The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
Low-sodium oxybate reduces excessive daytime sleepiness and improves nighttime sleep quality in participants with narcolepsy
This conclusion is most relevant to: Participants with narcolepsy type 1 (NT1, n=16) or type 2 (NT2, n=18) who completed the study (total n=34).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study. (Neurology and therapy, 2026) —
How It Works
The proposed biological pathway:
- ▸LXB contains calcium, magnesium, potassium, and sodium oxybates
- ▸Oxybate acts on GABA-B receptors to promote slow-wave sleep
- ▸Reduces transitions to lighter sleep stages and nocturnal awakenings
- ▸Result: Increased deep sleep duration and reduced daytime sleepiness
Who Might Benefit
Evidence fit by population:
- ▸Participants with narcolepsy type 1 (NT1, n=16) or type 2 (NT2, n=18) who completed the study (total n=34)
Recommended Dose
Individualized dose via titration over 2-8 weeks; specific dose not reported in abstract
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Open-label design without placebo control limits causal inference
- ▸Small sample size (n=34 completers) reduces generalizability
- ▸Short treatment duration (5-12 weeks) does not assess long-term efficacy or safety
Frequently Asked Questions
What is low-sodium oxybate (LXB) used for?▼
LXB (Xywav) is approved for treating excessive daytime sleepiness or cataplexy in people aged 7 years and older with narcolepsy, and for idiopathic hypersomnia in adults.
How was the effectiveness of LXB measured in the DUET study?▼
Effectiveness was measured using the Epworth Sleepiness Scale (ESS), nocturnal polysomnography (PSG), Narcolepsy Severity Scale (NSS/NSS-2), Patient Global Impression of Severity and Change, and daily eDiaries for sleep quality and cataplexy.
What were the main side effects of LXB in this study?▼
The most common treatment-emergent adverse events were nausea, dizziness, headache, drowsiness, and vomiting, consistent with the known safety profile of LXB.
Did LXB improve nighttime sleep in participants with narcolepsy?▼
Yes, LXB significantly increased deep sleep (N3) duration by about 45 minutes, reduced transitions to lighter sleep stages, and decreased nocturnal awakenings.
References
- 1.Schneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Cairns A. “Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study..” Neurology and therapy, 2026. PMID: 42060037 DOI: 10.1007/s40120-026-00921-3